Two small molecule agonists of glucagon-like peptide-1 receptor modulate the receptor activation response differently

Biochemical and Biophysical Research Communications

Volumn 417, Issue 1, 2012, Pages 558-563

  Cheong, Ye Hwang ^a,b   Kim, Mi Kyung ^a   Son, Moon Ho ^a   Kaang, Bong Kiun ^b  

^a Dong A Pharmaceutical Company   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Calcium influx; Compound 2; Compound B; GLP 1; GLP 1R

Indexed keywords

2 (6,7 DIHLORO 2 METHYLSULFONYL 2 N TERT BUTYLAMINOQUINOXALINE); [4 [3 (BENZYLOXY)PHENYL] 2 (ETHYLSULFINYL) 6 (TRIFLUOROMETHYL)PYRIMIDINE]; CALCIUM; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HORMONE RECEPTOR STIMULATING AGENT; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING;

ANIMALS; CALCIUM; CHO CELLS; CRICETINAE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDES; PYRIMIDINES; QUINOXALINES; RECEPTORS, GLUCAGON; SULFONES; VENOMS;

EID: 84855817124     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2011.12.004     Document Type: Article

References (19)

1. Drucker D.J. The biology of incretin hormones. Cell Metabolism 2006, 3:153-165.
2. 2+ channel activity. Endocrinology 1993, 133:1685-1692.
3. Legakis I.N., Tzioras C., Phenekos C. Decreased glucagon-like peptide 1 fasting levels in type 2 diabetes. Diabetes Care 2003, 26:252.
4. Garber A.J. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care 2011, 34:S279-S284.
5. Nauck M.A., Kleine N., Orskov C., Holst J.J., Willms B., Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993, 36:741-744.
6. Zander M., Madsbad S., Madsen J.L., Holst J.J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359:824-830.
7. Vilsbøll T., Agersø H., Krarup T., Holst J.J. Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. Journal of Clinical Endocrinology and Metabolism 2003, 88:220-224.
8. DeFronzo R.A., Ratner R.E., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
9. Knudsen L.B., Nielsen P.F., Huusfeldt P.O., Johansen N.L., Madsen K., Pedersen F.Z., et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. Medicinal Chemistry 2000, 43:1664-1669.
10. Nauck M.A., Meier J.J. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regulatory Peptides 2005, 128:135-148.
11. Montrose-Rafizadeh C., Yang H., Rodgers B.D., Beday A., Pritchette L.A., Eng J. High potency antagonists of the pancreatic glucagon-like peptide-1 receptor. Journal of Biological Chemistry 1997, 272:21201-21206.
12. Knudsen L.B., Kie D., Teng M., Behrens C., Bhumralkar D., Kodra J.T., et al. Small-molecule agonists for the glucagon-like peptide 1 receptor. Proceedings of the National Academy of Science 2007, 104:937-942.
13. Chen D., Liao J., Li N., Zhou C., Liu Q., Wang G., et al. A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice. Proceedings of the National Academy of Science 2007, 104:943-948.
14. Teng M., Johnson M.D., Thomas C., Kiel D., Lakis J.N., Kercher T., et al. Small molecule ago-allosteric modulators of the human glucagon-like peptide-1 (hGLP-1) receptor. Bioorganic & Medicinal Chemistry Letters 2007, 17:5472-5478.
15. Sloop K.W., Willard F.S., Brenner M.B., Ficorilli J., Valasek K., Showalter A.D., et al. Novel small molecule glucagon-like peptide-1 receptor agonist stimulates insulin secretion in rodents and from human islets. Diabetes 2010, 59:3099-3107.
16. Coopman K., Huang Y., Johnston N., Bradley S.J., Wilkinson G.F., Willars G.B. Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule ago-allosteric agent " compound 2" at the GLP-1 receptor. Journal of Pharmacology and Experimental Therapeutics 2010, 334:795-808.
17. Lin F., Wang R. Molecular modeling of the three-dimensional structure of GLP-1R and its interactions with several agonists. Journal of Molecular Modeling 2009, 15:53-65.
18. Rees S., Morrow D., Kenakin T. GPCR drug discovery through the exploitation of allosteric drug binding sites. Receptors and Channels 2002, 8:168-261.
19. Jensen A.A., Spalding T.A. Allosteric modulation of G-protein coupled receptors. European Journal of Pharmaceutical Sciences 2004, 21:407-420.